ReviewACS pharmacology & translational science2025
The Role of Proteomics and Genomics in the Development of Colorectal Cancer Diagnostic Tools and Potential New Treatments.
Review in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Diagnostic Potential of Exosomes in Colorectal Cancer: Current Advances and Future Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Large language model-augmented offline reinforcement learning framework for sepsis management in critical care.NPJ digital medicine · 2026Article
- The role of neddylation in colorectal cancer and its therapeutic potential.Discover oncology · 2025Review
- Liquid Biopsy and Multi-Omic Biomarkers in Breast Cancer: Innovations in Early Detection, Therapy Guidance, and Disease Monitoring.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complex molecular mechanisms involving genetic and epigenetic modifications contribute to colorectal cancer (CRC), which remains a significant threat to world health. This review elucidates the role of proteomics and genomics in the progression, diagnosis, and treatment of colorectal cancers. All potential key pathways involved in CRC, including WNT, MAPK, PI3K, and TGF-β pathways, are reviewed with a systematic analysis, concluding with their involvement in tumorigenesis and therapeutic resistance. Emerging next-generation sequencing technologies revealed critical mutations that are relevant to CRC development. Proteomics has contributed to identifying biomarkers and post-translational modifications that hold promise for targeted therapies. Recent technological advances have provided functional insights into protein signaling networks and pathways through mass spectrometry and integrated proteogenomic approaches. This work emphasizes biomarker-driven translational efforts that integrate genomic insights with protein expression profiles to refine personalized treatments. The application of innovations in liquid biopsy and computational biology advocates for precision medicine paths to improve the outcomes for CRC. Now, pharmacoproteomics offers novel domains for drug discovery and resistance management and serves as a foundation for comprehensive CRC treatment paradigms.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.